Jason Andrade, MD, director of electrophysiology, Vancouver General Hospital, and principal investigator of the PROGRESSIVE AF trial, explains how cryoablation can be used as a frontline treatment for atrial fibrillation (AFib) before drugs in this AHA late-breaker. 

The SPYRAL HTN-ON MED renal denervation trial failed to show that renal denervation was superior to sham control at improving ambulatory blood pressure (ABPM), but that might have been due to patient lifestyle changes during COVID-19.

Brian Lindman, MD, medical director of the Structural Heart and Valve Center, Vanderbilt University Medical Center, explains the new American Heart Association (AHA) Target Aortic Stenosis (AS) program to screen with echo to find more AS patients. 

FDA Commissioner Robert Califf, MD, who is a cardiologist, spoke at the opening session of the American Heart Association about the need to step up and address two major problems in the American healthcare system. 

The American Heart Association 2022 Scientific Sessions included 35 late-breaking studies and 39 featured science sessions presented at the meeting in Chicago, Nov. 5-7. Here is the list of all these studies with links to more information on the data.

Manesh R. Patel, MD, chair of AHA Scientific Sessions program, explains what he saw as the top takeaways from AHA 2022.

“The evidence shows increasingly that it’s time to rethink how we approach the treatment of AFib,” one researcher said.

James Udelson, MD, an investigator involved with the PRECISE trial, explained how patient outcomes were improved by 70% from the current standard of care.